Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV

被引:38
作者
Wang, Yong-shan [1 ]
Ouyang, Wei [1 ]
Liu, Xiao-juan [1 ,2 ]
He, Kong-wang [1 ]
Yu, Sheng-qing [3 ]
Zhang, Hai-bin [2 ]
Fan, Hong-jie [2 ]
Lu, Cheng-ping [2 ]
机构
[1] Jiangsu Acad Agr Sci, Inst Vet Med, Nanjing 210014, Peoples R China
[2] Nanjing Agr Univ, Coll Vet Med, Dept Microbiol & Immunol, Nanjing 210095, Jiangsu, Peoples R China
[3] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Shanghai 200241, Peoples R China
基金
中国国家自然科学基金;
关键词
Infectious bursal disease virus; Hepatitis B virus core particle; Virus-like particle; Chimeric VLP; Mimotope vaccine; RECOMBINANT VP2 VACCINE; CPG OLIGODEOXYNUCLEOTIDE; ANTIBODY-RESPONSES; DNA VACCINE; DISPLAY; ANTIGEN; SURFACE; GENE; PREVENTION; EPITOPES;
D O I
10.1016/j.vaccine.2012.01.040
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Current infectious bursal disease virus (IBDV) vaccines suffer from maternal antibody interference and mimotope vaccines might be an alternative. Previously we demonstrated an IBDV VP2 five-mimotope polypeptide, 5EPIS, elicited protective immunity in chickens. In the current study, the 5epis gene was inserted into a plasmid carrying human hepatitis B virus core protein (HBc) gene at its major immunodominant region site. The recombinant gene was efficiently expressed in Escherichia coli to produce chimeric protein HBc-5EPIS which self-assembles to virus-like particles (VLP). Two-week old specific-pathogen-free chickens were immunized intramuscularly with HBc-5EPIS VLP or 5EPIS polypeptide without adjuvant (50 mu g/injection) on day 0, 7, 14 and 21. Anti-5EPIS antibody was first detected on day 7 and day 21 in HBc-5EPIS and 5EPIS groups, respectively; on day 28, anti-5EPIS titers reached 12,800 or 1600 by ELISA, and 3200 or 800 by virus neutralization assay in HBc-5EPIS and 5EPIS groups, respectively. No anti-5EPIS antibody was detected in the buffer control group throughout the experiment. Challenge on day 28 with a virulent IBDV strain (GX8/99) resulted in 100%, 40.0% and 26.7% survival for chickens immunized with HBc-5EPIS, 5EPIS and buffer, respectively. These data suggest epitope presentation on chimeric VLP is a promising approach for improving mimotope vaccines for IBDV. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2125 / 2130
页数:6
相关论文
共 42 条
[1]   EXPRESSION IN ESCHERICHIA-COLI OF CDNA FRAGMENTS ENCODING THE GENE FOR THE HOST-PROTECTIVE ANTIGEN OF INFECTIOUS BURSAL DISEASE VIRUS [J].
AZAD, AA ;
FAHEY, KJ ;
BARRETT, SA ;
ERNY, KM ;
HUDSON, PJ .
VIROLOGY, 1986, 149 (02) :190-198
[2]   Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titred maternally derived antibody [J].
Bublot, M. ;
Pritchard, N. ;
Le Gros, F.-X. ;
Goutebroze, S. .
JOURNAL OF COMPARATIVE PATHOLOGY, 2007, 137 :S81-S84
[3]   3-DIMENSIONAL STRUCTURE OF HEPATITIS-B VIRUS CORE PARTICLES DETERMINED BY ELECTRON CRYOMICROSCOPY [J].
CROWTHER, RA ;
KISELEV, NA ;
BOTTCHER, B ;
BERRIMAN, JA ;
BORISOVA, GP ;
OSE, V ;
PUMPENS, P .
CELL, 1994, 77 (06) :943-950
[4]  
Cui ZhiZhong Cui ZhiZhong, 2002, Chinese Journal of Virology, V18, P162
[5]  
Fodor I, 1999, ACTA VET HUNG, V47, P481, DOI 10.1556/AVet.47.1999.4.8
[6]   Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile [J].
Garcon, Nathalie ;
Wettendorff, Martine ;
Van Mechelen, Marcelle .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (05) :667-677
[7]   Virus-like particles: Passport to immune recognition [J].
Grgacic, Elizabeth V. L. ;
Anderson, David A. .
METHODS, 2006, 40 (01) :60-65
[8]   A recombinant newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV [J].
Huang, ZH ;
Elankumaran, S ;
Yunus, AS ;
Samal, SK .
JOURNAL OF VIROLOGY, 2004, 78 (18) :10054-10063
[9]   Genetic heterogeneity in the VP2 gene of infectious bursal disease viruses detected in commercially reared chickens [J].
Jackwood, DJ ;
Sommer, SE .
AVIAN DISEASES, 1998, 42 (02) :321-339
[10]  
Jegerlehner A, 2002, EUR J IMMUNOL, V32, P3305, DOI 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO